• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

InforMedix' Med-eMonitor Improves Patient Medication Adherence To Over 92%, Reduces Hemoglobin A1c Levels By 18.5%, In Type II Diabetes Medication Management Program

Posted on: Monday, 13 February 2006, 09:00 CST

Significant Reduction of Key Diabetes Biomarker that Predicts Cost, Morbidity and Mortality; St. Vincent Healthcare Program Benefits Rural and Frontier Montana Patients

InforMedix Holdings, Inc. (OTCBB:IFMX) announced today that its Med-eMonitor System improved mean medication adherence rates to over 92% compared to a baseline medication adherence rate of 40%. InforMedix' Med-eMonitor System also reduced Hemoglobin A1c (HbA1c) levels by an average of 18.5% in a 3 month period (p value less than .002), in a medication management program involving Type II Diabetes patients in Montana. A reduction in HbA1c is associated with improved lifespan and morbidity and a significant reduction in healthcare costs in the treatment of Diabetes patients.

The August 2004 issue of Current Medical Research & Opinion published a study demonstrating that a reduced HbA1c level of 10% has been associated with a cost reduction of $10,800 per patient, and an increased life expectancy of one year. The June 2005 issue of Medical Care, a journal by the American Public Health Association, published a study demonstrating that Diabetes patients who are highly compliant with their treatment programs have a 13% hospitalization risk for a diabetes-related problem, but patients with low compliance have more than twice the risk at 30%. The combined drug and medical costs for the most compliant patients average $4,570, which is almost 50 percent below the $8,867 cost for the least compliant group. Proper screening and management of the disease by the patient can reduce the complication rate by half, resulting nationally in savings of $54 billion per year.

The program was conducted at St. Vincent Healthcare in Billings, Montana and involved patients using the Med-eMonitor, InforMedix's medication and care plan adherence platform to monitor responses to multiple specific medications, including the relationship between medication compliance, blood glucose and HbA1c levels. "St. Vincent has been very excited to participate in this pioneering program that is demonstrating the benefits of improved medication adherence," said David Irion, Executive Director of the St. Vincent Healthcare Foundation. "These results in our remote rural diabetic patients demonstrate that the challenges related to providing direct and immediate care for remote populations can be overcome by utilizing the right approach and tools, like the Med-eMonitor System. We anticipate a wider role for the Med-eMonitor System in our Center for Healthy Aging, to assist St. Vincent in monitoring chronically ill senior citizens in remote rural and frontier regions of Montana."

The interim results of the Program were presented by Bonne Farberow, RN, CCRA, CCRP, Vice President, Clinical Care Experts, Inc and Project Director, Division of Cardiology, the Hospital of the University of Pennsylvania, at the Disease Management Congress in Orlando, Florida. Ms Farberow's presentation was entitled, "Strategies to Improve Adherence: Ensuring Medication Adherence through Successful Disease Management Programs." Ms. Farberow, Project Director for the St. Vincent Diabetes Study, added, "The InforMedix field support personnel are extremely responsive to the patients and healthcare professionals. They have delivered on every commitment they made to us. The Med-eMonitor System has been well received by the patients and medical and nursing staffs participating in our study. We have successfully monitored patients living at a distance from our clinic, and improved our monitoring of these patients between visits."

Dr. Bruce Kehr, Chairman and CEO of InforMedix commented, "We are thrilled with the medication adherence and HbA1c results that were achieved in this program using our Med-eMonitor System. The results - medication adherence rates of over 92% - are consistent with the adherence rates of over 90% in other studies that used the Med-eMonitor in patients suffering from congestive heart failure and schizophrenia; and the average reduction in HbA1c of 18.5%, with a p- value signifying a high degree of statistical significance, correlates with significant reductions in morbidity, mortality, and cost. Type II Diabetes is becoming a major public health problem, with over one million newly diagnosed patients in the US each year. Given the consequences of non-adherence to the treatment regimen, including costly hospitalizations and disrupted lives, InforMedix' Med-eMonitor also received high marks from a majority of patients. Comments from the patients include, "You don't know what a difference this has made in my life. You all walk on water to me!" to "The Med-eMonitor is so cool, that my glucose was normal for the first time in over a year. The Med-eMonitor has changed my life. I can't say enough good things about it!"

InforMedix has developed the Med-eMonitor System as The Medication Adherence Solution for disease management and clinical drug trials markets. InforMedix has integrated a portable patient-interactive monitoring device, hardware, software and networked communications system to enable disease management programs, pharmaceutical and biotechnology companies, and medical researchers to efficiently monitor and manage patients' medication compliance, protocol adherence, clinical response, and drug safety. Med-eMonitor is specifically designed to improve patient medication compliance and protocol adherence in disease management and clinical drug trials programs. The Med-eMonitor System leverages InforMedix's strong intellectual property consisting of 15 issued patents and 12 patents pending. InforMedix's patents have been cited as prior art by patent examiners in over 150 other issued patents. To find out more about InforMedix, Inc. (OTCBB: IFMX), visit our website at www.informedix.com.

This report contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. These statements include: "(b)y improving medication adherence, the Med-eMonitor System, combined with traditional care management services, may produce a significant return-on-investment for Managed Care and Disease Management Organizations, and the Centers for Medicare and Medicaid Services (CMS)." References made to the discussion of the risk factors are detailed in the Company's filings with the Securities and Exchange Commission, including our Annual Report on Form 10-KSB for the year ended December 31, 2004, our prospectus dated March 28, 2005 and our other filings with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise.

Source: Business Wire

More News in this Category